vs

Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Shimmick Corp (SHIM). Click either name above to swap in a different company.

Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($196.0M vs $141.9M, roughly 1.4× Shimmick Corp). Shimmick Corp runs the higher net margin — -3.1% vs -14.6%, a 11.5% gap on every dollar of revenue. Axsome Therapeutics, Inc. produced more free cash flow last quarter ($-18.7M vs $-28.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs -10.1%).

Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.

Shimmick Corp is a U.S.-based heavy civil construction firm specializing in building and upgrading critical public infrastructure, including water facilities, transportation systems, dams, and environmental remediation projects. It primarily serves federal, state, and local government clients across North America, delivering complex large-scale construction solutions for public sector segments.

AXSM vs SHIM — Head-to-Head

Bigger by revenue
AXSM
AXSM
1.4× larger
AXSM
$196.0M
$141.9M
SHIM
Higher net margin
SHIM
SHIM
11.5% more per $
SHIM
-3.1%
-14.6%
AXSM
More free cash flow
AXSM
AXSM
$10.0M more FCF
AXSM
$-18.7M
$-28.7M
SHIM
Faster 2-yr revenue CAGR
AXSM
AXSM
Annualised
AXSM
61.7%
-10.1%
SHIM

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
AXSM
AXSM
SHIM
SHIM
Revenue
$196.0M
$141.9M
Net Profit
$-28.6M
$-4.4M
Gross Margin
7.6%
Operating Margin
-13.8%
-2.2%
Net Margin
-14.6%
-3.1%
Revenue YoY
65.0%
Net Profit YoY
61.9%
EPS (diluted)
$-0.55
$-0.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXSM
AXSM
SHIM
SHIM
Q4 25
$196.0M
$141.9M
Q3 25
$171.0M
$128.4M
Q2 25
$150.0M
$122.1M
Q1 25
$121.5M
$103.6M
Q4 24
$118.8M
Q3 24
$104.8M
$166.0M
Q2 24
$87.2M
$90.6M
Q1 24
$75.0M
$120.0M
Net Profit
AXSM
AXSM
SHIM
SHIM
Q4 25
$-28.6M
$-4.4M
Q3 25
$-47.2M
$-8.5M
Q2 25
$-48.0M
$-9.8M
Q1 25
$-59.4M
$-38.5M
Q4 24
$-74.9M
Q3 24
$-64.6M
$-1.6M
Q2 24
$-79.3M
$-51.4M
Q1 24
$-68.4M
$-33.3M
Gross Margin
AXSM
AXSM
SHIM
SHIM
Q4 25
7.6%
Q3 25
6.3%
Q2 25
3.8%
Q1 25
-20.1%
Q4 24
Q3 24
7.3%
Q2 24
-34.4%
Q1 24
-13.2%
Operating Margin
AXSM
AXSM
SHIM
SHIM
Q4 25
-13.8%
-2.2%
Q3 25
-27.0%
-5.5%
Q2 25
-24.5%
-7.3%
Q1 25
-46.9%
-39.3%
Q4 24
-61.1%
Q3 24
-59.8%
0.7%
Q2 24
-89.5%
-53.0%
Q1 24
-89.7%
-26.5%
Net Margin
AXSM
AXSM
SHIM
SHIM
Q4 25
-14.6%
-3.1%
Q3 25
-27.6%
-6.6%
Q2 25
-32.0%
-8.0%
Q1 25
-48.9%
-37.1%
Q4 24
-63.1%
Q3 24
-61.7%
-0.9%
Q2 24
-91.0%
-56.7%
Q1 24
-91.1%
-27.8%
EPS (diluted)
AXSM
AXSM
SHIM
SHIM
Q4 25
$-0.55
$-0.12
Q3 25
$-0.94
$-0.25
Q2 25
$-0.97
$-0.28
Q1 25
$-1.22
$-0.92
Q4 24
$-1.54
Q3 24
$-1.34
$-0.05
Q2 24
$-1.67
$-1.83
Q1 24
$-1.44
$-1.30

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXSM
AXSM
SHIM
SHIM
Cash + ST InvestmentsLiquidity on hand
$322.9M
$17.6M
Total DebtLower is stronger
$57.5M
Stockholders' EquityBook value
$88.3M
$-52.7M
Total Assets
$689.8M
$218.5M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXSM
AXSM
SHIM
SHIM
Q4 25
$322.9M
$17.6M
Q3 25
$325.3M
$21.4M
Q2 25
$303.0M
$16.3M
Q1 25
$300.9M
$33.7M
Q4 24
$315.4M
Q3 24
$327.3M
$26.0M
Q2 24
$315.7M
$22.4M
Q1 24
$331.4M
$27.3M
Total Debt
AXSM
AXSM
SHIM
SHIM
Q4 25
$57.5M
Q3 25
$36.4M
Q2 25
$31.4M
Q1 25
$9.5M
Q4 24
Q3 24
$39.9M
Q2 24
Q1 24
$31.5M
Stockholders' Equity
AXSM
AXSM
SHIM
SHIM
Q4 25
$88.3M
$-52.7M
Q3 25
$73.7M
$-49.5M
Q2 25
$73.1M
$-42.6M
Q1 25
$53.2M
$-34.7M
Q4 24
$57.0M
Q3 24
$92.9M
$973.0K
Q2 24
$102.9M
$436.0K
Q1 24
$144.0M
$38.1M
Total Assets
AXSM
AXSM
SHIM
SHIM
Q4 25
$689.8M
$218.5M
Q3 25
$669.3M
$203.0M
Q2 25
$639.8M
$227.7M
Q1 25
$596.7M
$233.9M
Q4 24
$568.5M
Q3 24
$561.5M
$346.7M
Q2 24
$548.2M
$344.5M
Q1 24
$545.7M
$378.0M
Debt / Equity
AXSM
AXSM
SHIM
SHIM
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
41.01×
Q2 24
Q1 24
0.83×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXSM
AXSM
SHIM
SHIM
Operating Cash FlowLast quarter
$-18.7M
$-23.7M
Free Cash FlowOCF − Capex
$-18.7M
$-28.7M
FCF MarginFCF / Revenue
-9.6%
-20.2%
Capex IntensityCapex / Revenue
0.0%
3.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-93.9M
$-27.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXSM
AXSM
SHIM
SHIM
Q4 25
$-18.7M
$-23.7M
Q3 25
$1.0M
$-3.8M
Q2 25
$-32.4M
$-38.2M
Q1 25
$-43.4M
$44.9M
Q4 24
$-26.2M
Q3 24
$-18.6M
$12.7M
Q2 24
$-30.1M
$-43.9M
Q1 24
$-53.5M
$-35.0M
Free Cash Flow
AXSM
AXSM
SHIM
SHIM
Q4 25
$-18.7M
$-28.7M
Q3 25
$988.0K
$-4.2M
Q2 25
$-32.4M
$-38.7M
Q1 25
$-43.7M
$44.4M
Q4 24
$-26.2M
Q3 24
$-18.7M
$10.3M
Q2 24
$-30.2M
$-46.8M
Q1 24
$-53.6M
$-39.6M
FCF Margin
AXSM
AXSM
SHIM
SHIM
Q4 25
-9.6%
-20.2%
Q3 25
0.6%
-3.2%
Q2 25
-21.6%
-31.7%
Q1 25
-36.0%
42.9%
Q4 24
-22.1%
Q3 24
-17.9%
6.2%
Q2 24
-34.6%
-51.7%
Q1 24
-71.4%
-33.0%
Capex Intensity
AXSM
AXSM
SHIM
SHIM
Q4 25
0.0%
3.5%
Q3 25
0.0%
0.3%
Q2 25
0.0%
0.4%
Q1 25
0.3%
0.5%
Q4 24
0.0%
Q3 24
0.1%
1.4%
Q2 24
0.1%
3.3%
Q1 24
0.1%
3.8%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AXSM
AXSM

Segment breakdown not available.

SHIM
SHIM

Shimmick Projects$106.8M75%
Non Core Projects$35.1M25%

Related Comparisons